Ichor (NASDAQ:ICHR) executives told investors the company is entering 2026 with strengthening demand across its primary semiconductor-served markets and growing contributions from its commercial space ...
With regard to Anavex 3-71, we will be advancing Anavex 3-71 towards pivotal clinical studies for the treatment of schizophrenia-related disorders. And now I would like to direct the call to Sandra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results